Remicade
E49851
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
All labels observed (3)
| Label | Occurrences |
|---|---|
| Remicade canonical | 9 |
| infliximab | 2 |
| infliximab-abda | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T391436 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Remicade Context triple: [Johnson & Johnson, notableProduct, Remicade]
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
E.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Remicade Target entity description: Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
E.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biologic drug
ⓘ
brand name drug ⓘ monoclonal antibody ⓘ |
| hasActiveIngredient | infliximab ⓘ |
| hasApprovalYear | 1998 ⓘ |
| hasATCCode | L04AB02 ⓘ |
| hasBiosimilar |
Avsola
ⓘ
Inflectra ⓘ Ixifi ⓘ Renflexis ⓘ |
| hasBlackBoxWarning |
malignancy
ⓘ
serious infections ⓘ |
| hasDosingRegimen | induction and maintenance ⓘ |
| hasDrugClass | tumor necrosis factor alpha inhibitor ⓘ |
| hasEffect |
reduces inflammation
ⓘ
suppresses immune response ⓘ |
| hasGenericName | infliximab ⓘ |
| hasHalfLife | approximately 7 to 12 days ⓘ |
| hasInductionSchedule | weeks 0 2 and 6 ⓘ |
| hasMaintenanceInterval | every 6 to 8 weeks ⓘ |
| hasMechanismOfAction | binds TNF alpha and neutralizes its activity ⓘ |
| hasMolecularType | chimeric monoclonal antibody ⓘ |
| hasPregnancyCategory | B (historical US FDA classification) ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasSpeciesComponents |
human
ⓘ
mouse ⓘ |
| hasTarget | tumor necrosis factor alpha ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isAdministeredIn |
hospital
ⓘ
infusion center ⓘ |
| isApprovedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| isCoDevelopedBy |
Janssen Biotech
ⓘ
Merck & Co. ⓘ |
| isContraindicatedIn |
patients with active serious infections
ⓘ
severe heart failure ⓘ |
| isManufacturedBy | Janssen Biotech ⓘ |
| isOftenUsedWith | methotrexate ⓘ |
| isUsedFor |
Crohn’s disease
ⓘ
ankylosing spondylitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
| isUsedIn |
adult patients
ⓘ
pediatric patients with certain indications ⓘ |
| mayCause |
hepatitis B reactivation
ⓘ
infusion reactions ⓘ reactivation of latent tuberculosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Remicade Description of subject: Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Referenced by (12)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
infliximab
this entity surface form:
infliximab-abda
this entity surface form:
infliximab